Abstract
In the pathogenesis of atherosclerosis, fibrinogen as the predominant clotting factor exerts its atherogenous effects through hemostatic and additional effects of blood flow. According to several epidemiologic studies fibrinogen has to be considered as a primary coronary risk factor comparable with other established risk factors, such as arterial hypertension and cho1estero1 .In patients with coronary artery disease, significantly elevated fibrinogen levels are found. Hyperfibrinogenemia can critically limit coronary blood flow in microcirculation due to fibrinogen-dependent increase in plasma viscosity and red-blood-cell aggregation- The importance of fibrinogen in microcirculatory blood flow can be demonstrated by the benefits of a reduction of plasma fibrinogen by fibrate therapy, e.g. fenofibrate treatment, LDL-cholesterol apheresis and a “chronically intermittent i/v urokinase therapy” in therapy-refractory patients with severe coronary artery disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Austen WG, Edwards JE, Frye RL, et al. (1976) — reporting system on patients evaluated for coronary artery disease. Report on othe Ad Hoc Committee for Grading of Coronary Artery Disease. Council on Cardiovascular Surgery, American Heart Association, Circulation 51 [suppl]: 5–10
Castelli WP (1984) Epidemiology of coronary heart diseases The Framing ham Study. Am — Med 76: 4–12
Chakrabarti R, Fearnley GR (1968) Effects of clofibrate on Fibrinolysis, platelet stickiness, plasmafibrinogen, and serum cholesterol. Lancet ii: 1007–1009
Gordon RI, Snyder GK, Tritel H, Taylor WJ (1974) Potential significance of plasma viscosity and hematocrit variations in myocardial infarction. Am Heart — 87: 175–182
Kampschmidt RF, Up church HF (1974) Effect of leucocytic endogenous mediator on plasma fibrinogen and haptoglobin. Proc Soc Exp Bio Med 146: 904–907
Kannel WB, Wolf PA, Castelli WP, D’Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. — Am Med Assoc 258: 1183–1186
Kleophas W, Leschke M, Tschope D, Martin J, Schauseil S, Schottenfeld Y, Strauer BE, Gries FA (1990) Akute Wirkungen der extrakorporalen LDL~Cholesterin-und Fibrinogen-Elimination auf Blutrheologie und Nikrozirkulation. Dtsch Hed Wschr 115: 3–7
Leschke M, Motz W, Blanke H, Meier M, Kaffarnik H, Strauer BE (1987) Die Wertigkeit rheo.logischer Parameter als Indikatoren der kdronaren Herzkrankheit im Vergleich zu Lipidparametern. InsStrauer BE et al. (eds): Fortschritte in der kardiovaskulären Hämorheologie. Münchener Wissenschaftliche Publikationen pp 39–44
Leschke M, Höffken H, Schmidtsdorff A, Blanke H, Egbring R, Joseph K, Strauer BE (1989) Einfluß von Fenofibrat auf Fibrinoqen-konzentration und Blutfluidität, Dtsch Hed Wschr 114: 939–944
Leschke M, Höffken H, Vogt H, Motz W, Strauer BE (1989) Intermittent urokinase therapy as — new strategy concept in untractable angina pectoris. — Am Coll Cardiol 13: 16 [abstract]
Leschke M, Strauer BE (1990) Die Bedeutung rheologischer Mechanismen in der Atherogenese. Arzneim Forsch (Drug Res) 40: 356–362
Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Thompson SG (1980) Hemostatic function and cardiovascular deaths early results of — prospective study. Lancet i: 1050–1055
Naito M, Hayaski T, Kuzuya M, Funaki C, Asai K, Kuzuya — (1990) Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cell in vitro, Atherosclerosis 83: 9–14
Niort G, Bulgarelli A, Lanader M, Pagano — (1988) Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerosis hyperfihrinogenemic patients, Atherosclerosis 71: 113–119
Schmid-Schonbein H, Rieger H, Fischer — (1980) Blood fluidity as — consequence of red cell fluidity’s flow properties of blood and flow behaviour of blood vascular diseases Angioloqy 31: 301–319
Seidel D, Wieland — (1982) Ein neues Verfahren zur selektiven Messung und extrakorporalen Elimination von Low-Density-Lipoproteinen. — Clin Chem Clin Biochem 20: 684–685
Stuart J, George AJ, Davies AJ, Aukland A, Hurlow RA (1981) Hematological stress syndrome in atherosclerosis. — Clin Pathol 34: 464–467
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Borst, M.M., Rabenau, O., Schoebel, F.C., Strauer, B.E., Leschke, M. (1993). Fibrinogen: Pathogenetical and Therapeutical Implications in Atherosclerosis. In: Catapano, A.L., Gotto, A.M., Smith, L.C., Paoletti, R. (eds) Drugs Affecting Lipid Metabolism. Medical Science Symposia Series, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1703-6_47
Download citation
DOI: https://doi.org/10.1007/978-94-011-1703-6_47
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4746-3
Online ISBN: 978-94-011-1703-6
eBook Packages: Springer Book Archive